Clinical trial
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
NCT00239356 · Otsuka Pharmaceutical Development & Commercialization, Inc., Industry · Completed
Key facts
| NCT number | NCT00239356 |
|---|---|
| Title | Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials |
| Official title | Aripiprazole (BMS-337039) for Outpatients With Schizophrenia Completing Aripiprazole Clinical Trials: A Non-Comparative Rollover Protocol |
| Lead sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc., Industry |
| Collaborators | Otsuka America Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 119 |
| Start date | Mar 1, 2003 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | Oct 17, 2005 |
| Last update posted | Dec 19, 2014 |
| Countries | Canada, Croatia, Czechia, France, Hungary, Netherlands, Poland, Romania, Russia, South Africa, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: